Dr Hendrik-Tobias Arkenau is the founding Medical Director of Sarah Cannon Research Institute UK, and is currently serving as the Executive Medical Director for SCRI UK and Clinical Lead for the Hospital Corporation of America International Cancer Service Line.
Dr Arkenau has vast experience in Early Oncology Clinical Drug Development with a special interest in gastrointestinal cancer and melanoma. He received his medical degree in 2000 at the Medical School Hanover, Germany, and completed his internship and specialist training in oncology in 2007. As part of SCRI’s collaboration with University College London (UCL), Dr Arkenau is appointed as a Professorial Research Associate on UCLs faculty and he holds an Honorary Consultant post with UCL Hospitals.
Sarah Cannon Research Institute UK’s remit is to incorporate all aspects of modern drug development from clinical pharmacology, molecular profiling to early clinical trials. The unique operational set-up aims to incorporate oncology drug development into day-to-day clinical practice with the ultimate goal to improve patient care.
Since its inauguration in 2010, Dr Arkenau has built up a trial portfolio of >80 early clinical trials. As Chief- and Principal Investigator he is actively involved in protocol development, toxicity review, pharmacokinetic analysis, biomarker and strategic development of new anti-cancer drugs, including immunotherapies. Dr Arkenau works as part of a multidisciplinary team of more than 40 members comprising of research nurses, operations specialist, project/data manager, regulatory adviser, QA-manager and other oncology specialists.
Dr Arkenau is Fellow of the Royal College of Physicians, and member of The German Cancer Society, ASCO, AACR and ESMO. He has presented multiple talks on the latest research in Oncology and has been Invited Speaker at several national/international meetings. Dr Arkenau has published articles in international peer-reviewed journals (e.g. Lancet, J Clin Oncol, Clin Cancer Res, Annals of Oncologyand others) and serves as ‘Contributing Associate Editor-in-Chief’ of the World Journal of Gastroenterology and ‘Associate Editor’ of World Journal of Cancer Research.
14+ years of experience in clinical practice and pharmaceutical industries, including Phase I-IV clinical development strategy and implementation, medical affairs strategy implementation, and trial management experience across the globe with in-depth expertise in solid tumors (breast, colon, lung and prostate cancers) and hematology (multiple myeloma)
Planning, coordinating and leading product launches, indication launches, ad boards, identifying research questions, data gaps and dissemination (publication) plans, ISS and sponsored programs, competitive market insights, review of promotional materials, scientific communications, medical education and health outcomes program
Strong matrix experience with internal partners such as commercial (marketing/sales), clinical development and other support functions
Extensive interactions and strong personal and professional relationships with highly recognized and respected Key Opinion Leaders.
Hamdy A. Azim is a Professor of Clinical Oncology at Cairo University in Egypt. He finished his doctorate degree on the management of non-Hodgkin's lymphoma in adults (1986). Dr Azim then obtained postdoctoral training at the Medical Oncology Department in NCI- Milan ( 1987) , the Medical Oncology Department in Curie Institute -Paris, France ( 1988-1989) , and at the Department of Adult Lymphoma and Bone Marrow Transplants, St. Louis Hospital in Paris( 1996) Dr Azim is a member of numerous societies including ASCO, ASH, ESMO , the European Blood and Marrow Transplantation Society (EBMT), and the American Society of Therapeutic Radiology (ASTRO). He sits on several international scientific / steering committees and has been invited as a speaker in more than 300 regional and international conferences. He also served as a speaker for the ASCO online educational programme. His main interests lie in breast cancer, molecular target therapies , bone metastases , Lymphoma and translation research where he has published more than 70 papers and 400 abstracts. Dr. Azim has been a principle investigator of many Multicenter international clinical trials mainly in breast cancer Dr Azim is an editor for the Journal of Clinical Lymphoma, The Lancet (Middle East edition), and the Journal of Clinical Oncology and Nuclear Medicine Cairo university. He was the chief editor of 2 educational books ( ASCO – PANARAB Lymphoma , 1999) and the MD Anderson Cancer Centre / Cairo University joint meeting (2006). Dr Azim serves as a referee for the Annals of Oncology Journal, THE BREAST , Chemotherapy Journal , Advances in Cancer Research and Journal of the Egyptian National Cancer Institute. He has been honoured with several awards including Scientist of the Year from the International Biographical Centre, Cambridge, UK (2002), the Order of Merit, Cambridge University (2002), the Best Arab Oncologist from the Lebanese Society of Medical Oncology (LSMO,2004) and the recognition award for significant contribution to the Oncology field in the middle east from UAE (Dubai -2013)
Dr Azim was the first to represent the Middle Eastern Region on the ASCO International Affairs Committee from 1997 to 2002. Together with international cancer research leaders, and the French president J. Chiraque, Dr Azim signed the “Charter of Paris against Cancer” on behalf of the Arab World in February 2000. On 2008, Dr. Azim was nominated as the chairman of the steering committee of the NCCN Middle East , which is responsible to set the guide lines of the management of certain cancers in the region. On January 2012 , Dr. Azim was elected to serve as the chairman of the department of clinical oncology ,faculty of medicine,Cairo University
Dr. Aysegul Sahin is an internationally recognized breast pathology expert who is a faculty member at M. D. Anderson Cancer Center since 1988. She received her medical doctor degree from University of Ankara in 1980, completed Anatomic and Clinical Pathology Residency at Oregon Health Science University, and did Surgical and Oncologic Surgical Pathology Fellowships at the University of Iowa Hospital and Clinics and the UT M. D. Anderson Cancer Center. Currently, she is the Section Head of Breast Pathology and Director of Education in the Department of Pathology and Breast Pathology Fellowship Program. She is also the Director of the Breast Tumor Bank. Dr. Sahin is actively involved with clinical and translation research programs related to breast cancer. She has published over 310 peer-reviewed manuscripts on breast pathology especially on morphologic features of invasive and in-situ carcinomas, and high-risk lesions biomarkers of breast cancer progression, prognostic and predictive marker evaluations in breast cancer. Dr. Sahin has also published multiple book chapters on pathology of breast lesions. She is an executive committee member of International Society of Breast Pathology and member of national and international pathology societies
Professor Peter Schmid was appointed as Chair in Cancer Medicine at Barts Cancer Institute, Queen Mary University London, in 2013. He is Clinical Director of Breast Cancer at the St. Bartholomew Cancer Centre and Honorary Consultant Medical Oncologist at Barts Hospital. Professor Schmid is also Lead of the Centre of Experimental Cancer Medicine at Barts Cancer Institute and the Barts/Brighton Experimental Cancer Medicine Centre. He leads the academic breast cancer programme and the cancer immune therapy group at Barts Cancer Institute.
Professor Schmid trained in medicine at Ludwig-Maximilians-University Munich, Technical University of Munich and University of Aberdeen. He was awarded scholarships by the 'Studienstiftung des deutschen Volkes', the 'Hanns-Seidel-Foundation', and the 'Deutscher Akademischer Austauschdienst'. Professor Schmid completed a MD on mitochondrial creatine kinase at the Technical University Munich. He subsequently trained at the University Hospital Charité in Berlin in internal medicine, haematology and oncology, where he became head of breast cancer research and the phase I programme. He completed his PhD at the Charité University in Berlin in 2005 and was awarded the "habilitation and venia legendi" and an external readership by the Charité University in 2006. From 2005-2010, Prof. Schmid was a Senior Clinical Lecturer and Director of the Hammersmith Early Clinical Trials Unit at Imperial College London. In 2010, he was appointed as Foundation Chair in Cancer Medicine at the University of Sussex, and he was Director of the Clinical Investigation and Research Unit at Brighton and Sussex University Hospitals until his move to Barts.
Professor Schmid’s specialist cancer interests are breast cancer, cancer immune therapy and early drug development. His research interests lie in stratified cancer medicine utilising novel biomarkers and innovative, biomarker-driven clinical trial strategies to develop new treatment strategies. Professor Schmid has successfully led more than 20 national/international academic clinical studies, ranging from phase I to III, and several translational research programmes. He leads a collaborative group to establish circulating tumour DNA as a biomarker and is principal investigator of 2 ongoing, prospective international biomarker studies on predictive epigenetics from circulating tumour DNA.
Professor Schmid is a member of several national and international cancer organizations and research groups and has been involved in international consensus meetings on the management of breast cancer. Professor Schmid is a member of ESMO breast cancer Faculty, the UK NCRN breast cancer study group and of the breast cancer and translational research steering groups of the German cooperative group of medical oncology. He has authored or –co-authored 165 publications and has published a book on the management of bone metastases (3rd edition).